Welcome to the post-event wrap-up of the 34th annual Antibody Engineering & Therapeutics US 2023 conference, recognized for being the leading knowledge and networking hub in the antibody industry. From December 13 – 16, 2023, more than 900 delegates from the antibody and protein community came together in San Diego to discuss the latest research, soak up critical updates from pioneers in the field, and network with their peers across the globe. Keynote speakers included Laura Walker, Ph.D, Head of Infectious Disease Biotherapeutics Discovery & Engineering at Moderna; Shannon Turley, Ph.D., Vice President and Therapeutic Area Head, Immunology and Regenerative Medicine at Genentech; Kole Roybal, Ph.D., Associate Professor, Microbiology & Immunology at UCSF School of Medicine; and Bassil Dahiyat, Ph.D., President and CEO of Xencor.
Across five days the industry discussed some of the most critical topics, including Neurodegenerative Diseases, Tumor Microenvironment in Antibody Therapy, Antibody Immune Agonist, Bi-Specifics, ADCs, Protein-Based Degraders, Immuno-oncology, T-Cells, VHH, and much more.
This e-book highlights key moments from the event and examines the significance of the research and insights on antibodies. Read on to get a sense of what the buzz was like on-site and learn more about the industry-shaping discussions that are shared at Antibody Engineering & Therapeutics US.
Click to read Antibodies U.S. eBook: Post-Event Report 2023
